Home/ Stocks/ RGNX

REGENXBIO Inc.

RGNX XNAS

$10.72 -0.28 (-2.48%) ▼ 15-min delayed

Open

$11.05

High

$11.39

Low

$10.31

Volume

1.39M

Market Cap

$744.63M

About REGENXBIO Inc.

Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 371 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$6.39M	$-90,051,000	$-1.72
FY 2025	$170.44M	$-193,878,000	$-3.76
Q3 2025	$29.73M	$-61,941,000	$-1.20
Q2 2025	$21.36M	$-70,871,000	$-1.38

Earnings & Analyst Ratings

Next Earnings: Wed, Nov 4, 2026

Calendar →

Related Market News

No specific coverage for RGNX yet. Check out our latest market news or earnings calendar.

Get RGNX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on REGENXBIO Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.